Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis

Yoshiyuki Morishita 1, *, Eiji Kusano 2, Daisuke Nagata 1
1 Division of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan
2 Utsunomiya Social Insurance Hospital, Tochigi, Japan

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 1671
Abstract HTML Views: 775
PDF Downloads: 379
Total Views/Downloads: 2825
Unique Statistics:

Full-Text HTML Views: 815
Abstract HTML Views: 431
PDF Downloads: 264
Total Views/Downloads: 1510

Creative Commons License
© Morishita et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke-city, Tochigi 329-0498, Japan; Tel.: 81-285-44-4869, Fax: 81-285-44-4869; E-mail:


The renin-angiotensin-aldosterone system (RAAS) blockers have been widely used in chronic kidney disease patients undergoing hemodialysis; however, whether RAAS blockers have beneficial effects for cardiovascular disease in those patients has not been fully defined. This review focuses on the effects of RAAS blockers in chronic kidney disease undergoing hemodialysis for cardiovascular disease.

Keywords: Hemodialysis, clinical study, renin, angiotensin I, angiotensin II, aldosterone, angiotensin-converting enzyme inhibitor, angiotensin receptor blockers, direct renin inhibitor, cardiovascular disease..